FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048472235> ?p ?o ?g. }

• W3048472235 endingPage "900" @default.
• W3048472235 startingPage "899.1" @default.
• W3048472235 abstract "Background: Antiphospholipid antibody (aPL) specificities are increasing, however the best accuracy for predicting the clinical manifestations of the diseases is still under debate. Objectives: To evaluate the clinical accuracy of aPL specificities both individually and/or in combination, to identify a panel of tests that may provide the best accuracy for predicting clinical manifestations of antiphospholipid syndrome (APS). Methods: We chart-reviewed patients that presented at San Giovanni Bosco Hospital in the last 5 years who tested persistently positive for at least one aPL[1]. Inclusion criteria comprehended: a)Primary APS(PAPS); b) Secondary APS(SAPS), c)aPL positive asymptomatic and d)Patients with clinical manifestations of APS and either inconsistent previous LA positivity and/or low-medium titers aPL(suspect APS). Results: A total of 122 patients were included in the study 38 PAPS, 31 SAPS, 23 aPL positive asymptomatic and 30 low titers APS patients). Table1 resumes the main clinical and laboratory characteristics of the patients included in the study. All patients were tested for five aPL: criteria aPL, anti-phosphatidylserine/prothrombin(aPS/PT) and anti-Beta2Glycoprotein I Domain I(β2GPI-D1). Among the single aPL positivity, β2GPI-D1 showed the best accuracy in predicting the clinical manifestations of APS (AUC 0.639,CI95% 0.539–0.74,p=0.011). Similarly, when investigating the possible combinations of aPL panels, the positivity for aPS/PT IgG/IgM and/or β2GPI-D1 showed the best accuracy in predicting the clinical manifestations of APS (AUC 0.698, CI95%0.604 –0.793, p<0.001) while triple criteria aPL IgG positivity had the best accuracy for predicting recurrences (AUC 0.720, CI95% 0.569–0.871, p=0.012). Results of the ROC curves are illustrated in Figure 1. Figure 1. When considering aPL asymptomatic patients and APS patients (both PAPS and SAPS), the only two aPL combinations that showed a statistically significant association with the APS group were aPS/PT IgG/IgM and/or β2GPI-D1 (OR 4.86,CI95%1.76-13.3,p<0.05) and Global APS Score >11 (OR 2.87, CI95% 1.08-7.6, p<0.05). Interestingly, also adding the patients with suspect APS to the equation, the combination of aPS/PT IgG/IgM and/or β2GPI-D1 remained statistically significant (OR 2.5,CI95%1.02-7.05 p<0.05). Conclusion: Combining anti-β2GPI D1 and aPS/PT improves the diagnostic power of aPL testing and might improve in risk stratification in patients with aPL positivity. References: [1] Miyakis S et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost [Internet]. 2006 Feb;4(2):295–306. Table 1. PAPS (n=38 ) SAPS (n=31 ) aPL+ (n=23 ) Low titers (n=30 ) Demographics Age at study inclusion; years (±SD) 50,2 (±13,7) 49,3 (±12,3) 48,78 (±12,8) 50,6 (±11,3) Clinical Characteristics Thrombosis; n, (%) 31 (82) 30 (97) 0 26 (87) Arterial; n, (%) 21 (55) 16 (52) 0 14 (47) Venous; n, (%) 15 (39) 16 (52) 0 13 (43) Pregnancy Morbidity*; n, (%) 8 (21) 3 (10) 0 5 (17) Recurrences of APS clinical manifestations; n, (%) 7 (18) 5 (16) 0 2 (7) Laboratory Profile LA; n, (%) 32 (84) 26 (84) 21 (91) 16 (53) aCL (IgG/M); n, (%) 25 (66) 22 (71) 15 (65) 14** (47) ß2GPI (IgG/M); n, (%) 26 (68) 23 (74) 15 (65) 14** (47) Triple aPL (IgG/M); n, (%) 23 (61) 19 (61) 13 (57) 4** (13) Triple aPL (IgG); n, (%) 17 (45) 16 (52) 10 (44) 0** aPS/PT (IgG/M); n, (%) 24 (63) 20 (65) 15 (65) 6 (20) ß2GPI-D1; n, (%) 13 (34) 15 (48) 3 (13) 4 (13) Triple aPL and aPS/PT (IgG/M); n, (%) 16 (42) 14 (45) 10 (44) 0** Triple aPL and ß2GPI-D1; n, (%) 12 (32) 12 (39) 3 (13) 0** aPS/PT (IgG) and/or ß2GPI-D1; n, (%) 22 (58) 24 (77) 7 (30) 6 (20) Cardiovascular Risk Factors Hypertension; n, (%) 15 (39) 14 (45) 5 (22) 9 (30) Hyperlipidemia; n, (%) 14 (37) 11 (35) 2 (9) 7 (23) Smoking; n, (%) 4 (11) 7 (23) 2 (9) 4 (13) Diabetes; n, (%) 4 (11) 2 (6) 1 (4) 1 (3) GAPSS; value (±SD) 13,8 (±6) 14 (±5,5) 12,6 (±5,3) 7,3 (±4,8) GAPSS >9; n, (%) 30 (79) 22 (71) 14 (61) 7 (23) GAPSS >14; n, (%) 17 (44) 16 (52) 11 (48) 2 (7) Disclosure of Interests: None declared" @default.
• W3048472235 created "2020-08-18" @default.
• W3048472235 creator A5012705049 @default.
• W3048472235 creator A5014323438 @default.
• W3048472235 creator A5017039749 @default.
• W3048472235 creator A5048345840 @default.
• W3048472235 creator A5054660181 @default.
• W3048472235 creator A5063790465 @default.
• W3048472235 creator A5073274706 @default.
• W3048472235 date "2020-06-01" @default.
• W3048472235 modified "2023-09-25" @default.
• W3048472235 title "FRI0589 CLINICAL ACCURACY OF ANTI-PHOSPHATIDYLSERINE/PROTHROMBIN AND ANTI-BETA2GLYCOPROTEIN I DOMAIN I FOR PREDICTING CLINICAL MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME" @default.
• W3048472235 cites W2054330426 @default.
• W3048472235 doi "https://doi.org/10.1136/annrheumdis-2020-eular.2330" @default.
• W3048472235 hasPublicationYear "2020" @default.
• W3048472235 type Work @default.
• W3048472235 sameAs 3048472235 @default.
• W3048472235 citedByCount "0" @default.
• W3048472235 crossrefType "journal-article" @default.
• W3048472235 hasAuthorship W3048472235A5012705049 @default.
• W3048472235 hasAuthorship W3048472235A5014323438 @default.
• W3048472235 hasAuthorship W3048472235A5017039749 @default.
• W3048472235 hasAuthorship W3048472235A5048345840 @default.
• W3048472235 hasAuthorship W3048472235A5054660181 @default.
• W3048472235 hasAuthorship W3048472235A5063790465 @default.
• W3048472235 hasAuthorship W3048472235A5073274706 @default.
• W3048472235 hasConcept C126322002 @default.
• W3048472235 hasConcept C159654299 @default.
• W3048472235 hasConcept C203014093 @default.
• W3048472235 hasConcept C2776874634 @default.
• W3048472235 hasConcept C2777910003 @default.
• W3048472235 hasConcept C2780868729 @default.
• W3048472235 hasConcept C32611913 @default.
• W3048472235 hasConcept C71924100 @default.
• W3048472235 hasConcept C90924648 @default.
• W3048472235 hasConceptScore W3048472235C126322002 @default.
• W3048472235 hasConceptScore W3048472235C159654299 @default.
• W3048472235 hasConceptScore W3048472235C203014093 @default.
• W3048472235 hasConceptScore W3048472235C2776874634 @default.
• W3048472235 hasConceptScore W3048472235C2777910003 @default.
• W3048472235 hasConceptScore W3048472235C2780868729 @default.
• W3048472235 hasConceptScore W3048472235C32611913 @default.
• W3048472235 hasConceptScore W3048472235C71924100 @default.
• W3048472235 hasConceptScore W3048472235C90924648 @default.
• W3048472235 hasIssue "Suppl 1" @default.
• W3048472235 hasLocation W30484722351 @default.
• W3048472235 hasOpenAccess W3048472235 @default.
• W3048472235 hasPrimaryLocation W30484722351 @default.
• W3048472235 hasRelatedWork W1903920296 @default.
• W3048472235 hasRelatedWork W1977645254 @default.
• W3048472235 hasRelatedWork W1992363163 @default.
• W3048472235 hasRelatedWork W2057576459 @default.
• W3048472235 hasRelatedWork W2091566690 @default.
• W3048472235 hasRelatedWork W2094629470 @default.
• W3048472235 hasRelatedWork W2414059406 @default.
• W3048472235 hasRelatedWork W2464068520 @default.
• W3048472235 hasRelatedWork W3134014675 @default.
• W3048472235 hasRelatedWork W4237124780 @default.
• W3048472235 hasVolume "79" @default.
• W3048472235 isParatext "false" @default.
• W3048472235 isRetracted "false" @default.
• W3048472235 magId "3048472235" @default.
• W3048472235 workType "article" @default.